Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
1(8%)
Results Posted
22%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_1
1
8%
Ph phase_3
2
17%
Ph phase_4
8
67%

Phase Distribution

1

Early Stage

0

Mid Stage

10

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
8(66.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 32 (16.7%)
Phase 48 (66.7%)
N/A1 (8.3%)

Trials by Status

recruiting18%
terminated18%
unknown18%
completed975%

Recent Activity

1 active trials
Showing 5 of 12
recruitingnot_applicable

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

NCT07400757
unknownphase_3

Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

NCT04882293
completedphase_4

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

NCT00442325
completedphase_4

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)

NCT00442845
terminatedphase_4

The Effect of Lipitor on Aortic Stenosis

NCT00590135
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07400757Not Applicable

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

Recruiting
NCT04882293Phase 3

Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Unknown
NCT00442325Phase 4

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

Completed
NCT00442845Phase 4

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)

Completed
NCT00590135Phase 4

The Effect of Lipitor on Aortic Stenosis

Terminated
NCT01766076Phase 3

Atorvastatin for HAART Suboptimal Responders

Completed
NCT00120055Phase 4

Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity

Completed
NCT01285544Phase 4

The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia

Completed
NCT00143741Phase 1

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

Completed
NCT01029522Phase 4

Dyslipidemia in Cardiovascular Disease

Completed
NCT00926614Phase 4

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

Completed
NCT00408382Phase 4

Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12